Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63(1):181–7.

Article  CAS  PubMed  Google Scholar 

Murley R. Axillary dissection in primary breast cancer. BMJ: Br Med J. 1991;302(6776):590–1.

Article  Google Scholar 

Hladiuk M, Huchcroft S, Temple W, Schnurr BE. Arm function after axillary dissection for breast cancer: a pilot study to provide parameter estimates. J Surg Oncol. 1992;50(1):47–52.

Article  CAS  PubMed  Google Scholar 

Ivens D, Hoe AL, Podd TJ, Hamilton CR, Taylor I, Royle GT. Assessment of morbidity from complete axillary dissection. Br J Cancer. 1992;66(1):136–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Breast. In: Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. editors. AJCC Cancer Staging Manual. New York, NY: Springer New York; 2002. pp. 223–40.

Google Scholar 

Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23 – 01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(10):1385–93.

Article  PubMed  Google Scholar 

Tjan-Heijnen VC, Buit P, de Widt-Evert LM, Ruers TJ, Beex LV. Micro-metastases in axillary lymph nodes: an increasing classification and treatment dilemma in breast cancer due to the introduction of the sentinel lymph node procedure. Breast Cancer Res Treat. 2001;70(2):81–8.

Article  CAS  PubMed  Google Scholar 

Rutledge H, Davis J, Chiu R, Cibull M, Brill Y, McGrath P, et al. Sentinel node micrometastasis in breast carcinoma may not be an indication for complete axillary dissection. Mod Pathol. 2005;18(6):762–8.

Article  PubMed  Google Scholar 

Maaskant-Braat AJ, van de Poll-Franse LV, Voogd AC, Coebergh JW, Roumen RM, Nolthenius-Puylaert MC, et al. Sentinel node micrometastases in breast cancer do not affect prognosis: a population-based study. Breast Cancer Res Treat. 2011;127(1):195–203.

Article  PubMed  Google Scholar 

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. Invasive breast Cancer Version 1.2016, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(3):324–54.

Article  PubMed  Google Scholar 

Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609–18.

Article  PubMed  Google Scholar 

Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258–64.

Article  PubMed  Google Scholar 

Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Osorio-Silla I, Gómez Valdazo A, Sánchez Méndez JI, York E, Díaz-Almirón M, Gómez Ramírez J, et al. Is it always necessary to perform an axillary lymph node dissection after neoadjuvant chemotherapy for breast cancer? Ann R Coll Surg Engl. 2019;101(3):186–92.

Article  CAS  PubMed  Google Scholar 

Giuliano AE, Edge SB, Hortobagyi GN. Eighth Edition of the AJCC Cancer staging Manual: breast Cancer. Ann Surg Oncol. 2018;25(7):1783–5.

Article  PubMed  Google Scholar 

Mathiesen O, Carl J, Bonderup O, Panduro J. Axillary sampling and the risk of erroneous staging of breast cancer. An analysis of 960 consecutive patients. Acta Oncol. 1990;29(6):721–5.

Article  CAS  PubMed  Google Scholar 

Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer. 1992;28a(8–9):1415–8.

Article  CAS  PubMed  Google Scholar 

Recht A, Houlihan MJ. Axillary lymph nodes and breast cancer: a review. Cancer. 1995;76(9):1491–512.

Article  CAS  PubMed  Google Scholar 

Meric F, Mirza NQ, Buzdar AU, Hunt KK, Ames FC, Ross MI, et al. Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer. Ann Surg Oncol. 2000;7(6):435–40.

Article  CAS  PubMed  Google Scholar 

Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005;23(36):9304–11.

Article  PubMed  Google Scholar 

Mougalian SS, Hernandez M, Lei X, Lynch S, Kuerer HM, Symmans WF, et al. Ten-year outcomes of patients with breast Cancer with Cytologically confirmed Axillary Lymph Node metastases and pathologic complete response after primary systemic chemotherapy. JAMA Oncol. 2016;2(4):508–16.

Article  PubMed  PubMed Central  Google Scholar 

van Nijnatten TJ, Simons JM, Moossdorff M, de Munck L, Lobbes MB, van der Pol CC, et al. Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases. Breast Cancer Res Treat. 2017;163(1):159–66.

Article  PubMed  PubMed Central  Google Scholar 

Wong SM, Almana N, Choi J, Hu J, Gagnon H, Natsuhara K, et al. Prognostic significance of residual axillary nodal micrometastases and isolated Tumor cells after neoadjuvant chemotherapy for breast Cancer. Ann Surg Oncol. 2019;26(11):3502–9.

Article  PubMed  Google Scholar 

Akay CL, Albarracin C, Torstenson T, Bassett R, Mittendorf EA, Yi M, et al. Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. Breast J. 2018;24(1):28–34.

Article  CAS  PubMed  Google Scholar 

Gimbergues P, Dauplat MM, Durando X, Abrial C, Le Bouedec G, Mouret-Reynier MA, et al. Intraoperative imprint cytology examination of sentinel lymph nodes after neoadjuvant chemotherapy in breast cancer patients. Ann Surg Oncol. 2010;17(8):2132–7.

Article  CAS  PubMed  Google Scholar 

Moo TA, Edelweiss M, Hajiyeva S, Stempel M, Raiss M, Zabor EC, et al. Is low-volume disease in the Sentinel Node after Neoadjuvant Chemotherapy an indication for Axillary Dissection? Ann Surg Oncol. 2018;25(6):1488–94.

Article  PubMed  PubMed Central  Google Scholar 

Weiss A, King C, Vincuilla J, Parker T, Portnow L, Nakhlis F, et al. Rates of pathologic nodal disease among cN0 and cN1 patients undergoing routine axillary ultrasound and neoadjuvant chemotherapy. Breast Cancer Res Treat. 2022;195(2):181–9.

Article  CAS  PubMed  Google Scholar 

Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P, et al. Locoregional Recurrence after Sentinel Lymph Node Dissection with or without Axillary dissection in patients with Sentinel Lymph Node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. Ann Surg. 2016;264(3):413–20.

Article  PubMed  Google Scholar 

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72.

Article  PubMed  Google Scholar 

Haque W, Verma V, Hatch S, Suzanne Klimberg V, Brian Butler E, Teh BS. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat. 2018;170(3):559–67.

Article  CAS  PubMed  Google Scholar 

Tao M, Chen S, Zhang X, Zhou Q. Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. Med (Baltim). 2017;96(51):e9384.

Article